{
    "id": 1834,
    "fullName": "CDKN2A del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2A del indicates a deletion of the CDKN2A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1029,
        "geneSymbol": "CDKN2A",
        "terms": [
            "CDKN2A",
            "ARF",
            "CDK4I",
            "CDKN2",
            "CMM2",
            "INK4",
            "INK4A",
            "MLM",
            "MTS-1",
            "MTS1",
            "P14",
            "P14ARF",
            "P16",
            "P16-INK4A",
            "P16INK4",
            "P16INK4A",
            "P19",
            "P19ARF",
            "TP16"
        ]
    },
    "variant": "del",
    "createDate": "09/19/2014",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10260,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9368,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18706,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibrance (palbociclib) treatment did not demonstrated clinical efficacy in heavily pre-treated gastrointestinal stromal tumor patients harboring CDKN2A homozygous or heterozygous deletion, with 86.4% (19/22) of patients demonstrated progressive disease at 4 months (PMID: 30979737; NCT01907607).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16390,
                    "pubMedId": 30979737,
                    "title": "Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30979737"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9367,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDKN2C in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2501,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human glioblastoma cell lines with a CDKN2A/CDKN2C codeletion demonstrated sensitivity to Palbociclib (PD0332991) (PMID: 20534551).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3184,
                    "pubMedId": 20534551,
                    "title": "Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20534551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2930,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Kisqali (ribociclib) inhibited proliferation of a Gleevec (imatinib)-resistant dermatofibroscarcoma cell line harboring deletion of both CDKN2A and CDKN2B and a PDGFB rearrangement (PMID: 25852058).",
            "molecularProfile": {
                "id": 10737,
                "profileName": "PDGFB fusion CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3535,
                    "pubMedId": 25852058,
                    "title": "CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25852058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9366,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDK6 amplification in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26838,
                "profileName": "CDK6 amp CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9501,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Kisqali (ribociclib) demonstrated preliminary efficacy in patients with advanced solid tumors and lymphomas, and 2/4 CCND1-amplified patients remaining on treatment for greater than 8 weeks also had co-deletion of CDKN2A and CDKN2B (PMID: 27542767).",
            "molecularProfile": {
                "id": 26860,
                "profileName": "CCND1 amp CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7226,
                    "pubMedId": 27542767,
                    "title": "A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542767"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11541,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease for a total of 15 months in a pancreatic ductal adenocarcinoma patient harboring EML4-ALK, along with CDKN2A/B deletion, MYC amplification, and TP53 L111fs (PMID: 28476735).",
            "molecularProfile": {
                "id": 28129,
                "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11543,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28131,
                "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11544,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28131,
                "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17522,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Ibrance (palbociclib) in combination with Zelboraf (vemurafenib) resulted in clinical improvement and stable disease in a patient with epithelioid glioblastoma harboring BRAF V600E and homozygous deletion of CDKN2A and CDKN2B, however, his disease progressed after 10 weeks on treatment (PMID: 31217909).",
            "molecularProfile": {
                "id": 32674,
                "profileName": "BRAF V600E CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 4129,
                "therapyName": "Palbociclib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19403,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 34074,
                "profileName": "CDKN2A del RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19335,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment resulted in enhanced inhibition of Rb1 phosphorylation and cell cycle progression in lung cancer cell lines harboring KRAS G12C and CDKN2A deletion, led to synergistic inhibition of cell growth in culture, and induced tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 34659,
                "profileName": "CDKN2A del KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination treatment synergistically inhibited tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8901,
                "therapyName": "AZD7648 + Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth, however, with decreased response compared to AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19481,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited viability of triple-negative breast cancer cells harboring wild-type ATM in culture, and induced tumor regression in a patient-derived xenograft (PDX) model harboring wild-type ATM, TP53 and BRCA2 mutations, CCNE1 amplification, and CDKN2A deletion (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6542,
            "profileName": "CDKN2A del",
            "profileTreatmentApproaches": [
                {
                    "id": 10598,
                    "name": "CDK Inhibitor (Pan)",
                    "profileName": "CDKN2A del"
                },
                {
                    "id": 10601,
                    "name": "CDK6 Inhibitor",
                    "profileName": "CDKN2A del"
                },
                {
                    "id": 10600,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CDKN2A del"
                },
                {
                    "id": 10599,
                    "name": "CDK4 Inhibitor",
                    "profileName": "CDKN2A del"
                }
            ]
        },
        {
            "id": 8470,
            "profileName": "CDKN2A del CDKN2C del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10737,
            "profileName": "PDGFB fusion CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26838,
            "profileName": "CDK6 amp CDKN2A del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26860,
            "profileName": "CCND1 amp CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28129,
            "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28131,
            "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32674,
            "profileName": "BRAF V600E CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34074,
            "profileName": "CDKN2A del RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34553,
            "profileName": "ATM wild-type BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34659,
            "profileName": "CDKN2A del KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34749,
            "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}